Toyama, Japan

Bunei Nagahashi

This inventor holds 3 USPTO granted patents. Top assignee: Toyama Chemical Co., Ltd.. Active years: 1982-1983.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Bunei Nagahashi. Retrieved from https://idiyas.com/inventor/bunei-nagahashi

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 9.0

ph-index = 3

Forward Citations = 22(Granted Patents)


Company Filing History:


Years Active: 1982-1983

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Bunei Nagahashi: Innovator in Antibacterial Compounds

Introduction

Bunei Nagahashi is a notable inventor based in Toyama, Japan. He has made significant contributions to the field of antibacterial compounds, particularly through his innovative processes for producing valuable intermediates used in cephalosporins.

Latest Patents

Nagahashi holds 3 patents, with his latest patents focusing on a novel process for producing 7-(substituted)amino-3-substituted thiomethyl cephem carboxylic acids. These compounds are recognized as important antibacterial agents for use in mammals, including humans. His work in this area has the potential to impact the pharmaceutical industry significantly.

Career Highlights

Bunei Nagahashi is associated with Toyama Chemical Co., Ltd., where he has been instrumental in advancing research and development in antibacterial compounds. His expertise and innovative approaches have contributed to the company's reputation in the pharmaceutical sector.

Collaborations

Nagahashi has collaborated with notable colleagues, including Isamu Saikawa and Shuntaro Takano. Their combined efforts have fostered a productive research environment, leading to advancements in their field.

Conclusion

Bunei Nagahashi's work exemplifies the importance of innovation in the development of antibacterial compounds. His contributions continue to influence the pharmaceutical industry and improve health outcomes.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…